Patrick M. Forde, MBBCh

Patrick Forde, MBBCh, PhD, explains why circulating tumor DNA testing falls short after lung cancer surgery and previews vaccine and KRAS G12C trials.

Patrick Forde, MBBCh, PhD, explains how he sequences neoadjuvant and adjuvant osimertinib and why genomic testing matters before lung cancer surgery.

Patrick Forde, MBBCh, PhD, explains how pathological complete response guides his decision to add adjuvant immunotherapy in resectable lung cancer.

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses the CheckMate-026 study, which demonstrated that first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses a study presented at ESMO 2016 on neoadjuvant nivolumab, in early stage resectable non-small-cell lung cancer (NSCLC).